PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland.
Front Public Health. 2022 Jun 28;10:909459. doi: 10.3389/fpubh.2022.909459. eCollection 2022.
To substantiate the beneficial effects of switching from cigarette smoking to heated tobacco products (HTP), this study conducted a time-trend analysis using data from the Japanese Medical Data Center (JMDC) database. Specifically, we assessed hospitalization numbers for chronic obstructive pulmonary disease (COPD) exacerbations and acute ischemic heart disease (IHD) before and after the introduction of HTPs in the Japanese market. This study replicated a previous study using a different Japanese real-world data source (Medical Data Vision). We retrieved the number of hospitalizations associated with the International Classification of Diseases-10 codes for COPD and IHD from 2010 to 2019-5 years before to 4 years after introducing HTPs in the Japanese market-from the JMDC database. Then, we used interrupted time-series analyses to test the hypothesis that the introduction of HTPs is associated with a reduction in hospitalizations for COPD (all codes), COPD exacerbation, COPD exacerbation plus lower respiratory tract infections (LRTI), and IHD, adjusting for age, sex, seasonality, and flu vaccination rates. Analysis of all available data from the JMDC database revealed a significant reduction in the number of hospitalizations for COPD (all codes; = 0.0001) and IHD using Diagnosis Procedure Combination data on causative disease flags ( < 0.00001). We also observed a non-significant reduction in hospitalizations for COPD plus LRTI as well as IHD after HTP introduction in Japan. This study confirmed the findings of our previous study where a decrease in hospitalizations due to COPD exacerbation after the introduction of HTPs in Japan was also shown. Nevertheless, these findings warrant further research to evaluate the impact of HTPs on the health of populations in other countries where these products have been introduced.
为了证实从吸烟转向加热烟草产品(HTP)的有益效果,本研究利用日本医疗数据中心(JMDC)数据库的数据进行了时间趋势分析。具体来说,我们评估了 HTP 在日本市场推出前后慢性阻塞性肺疾病(COPD)恶化和急性缺血性心脏病(IHD)的住院人数。本研究使用来自日本的不同真实世界数据源(Medical Data Vision)复制了之前的一项研究。我们从 JMDC 数据库中检索了与 COPD 和 IHD 的国际疾病分类第 10 版代码相关的住院人数,时间范围为 2010 年至 2019 年(HTP 在日本市场推出前 5 年至推出后 4 年)。然后,我们使用中断时间序列分析来检验 HTP 引入与 COPD(所有代码)、COPD 恶化、COPD 恶化加下呼吸道感染(LRTI)和 IHD 住院人数减少相关的假设,调整了年龄、性别、季节性和流感疫苗接种率。对来自 JMDC 数据库的所有可用数据的分析显示,使用病因疾病标志的诊断程序组合数据,COPD(所有代码)的住院人数减少具有统计学意义( = 0.0001)和 IHD( < 0.00001)。我们还观察到在 HTP 引入日本后,COPD 加 LRTI 以及 IHD 的住院人数减少,但无统计学意义。本研究证实了我们之前的研究结果,即在 HTP 引入日本后,由于 COPD 恶化导致的住院人数减少。然而,这些发现需要进一步研究,以评估 HTP 对其他引入这些产品的国家人群健康的影响。